Evidence map›Paper›PMID 24930888›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

The hypocretin/orexin system mediates the extinction of fear memories.

África Flores, Victòria Valls-Comamala, Giulia Costa, Rocío Saravia, Rafael Maldonado, Fernando Berrendero

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593682 (The Role of Orexin in Human Panic Disorder), which is not on this map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593682 phase4completednot on this mapstarted 2016, after this paper: background citation

The Role of Orexin in Human Panic Disorder

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled3ConditionsPanic DisorderArmssuvorexant, placebo
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 128 citations in OpenAlex.

  1. Trial
  2. Article
  3. Selective orexin receptor cross-over treatment increases resilience and expression of neuroplastic signaling genes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  4. Article
  5. COAddiction biology · 2026
    Article
  6. Associations of COPhysiology & behavior · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Animal models of human insomnia.Journal of sleep research · 2023
    Review
  18. COPhysiology & behavior · 2023
    Article
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

África FloresLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, Barcelona, Spain.
Victòria Valls-ComamalaLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, Barcelona, Spain.
Giulia CostaDepartment of Biomedical Sciences, Section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy.
Rocío SaraviaLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, Barcelona, Spain.
Rafael MaldonadoLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, Barcelona, Spain.
Fernando BerrenderoLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, PRBB, C/ Doctor Aiguader 88, Barcelona, Spain.
University of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anxiety disorders are often associated with an inability to extinguish learned fear responses. The hypocretin/orexin system is involved in the regulation of emotional states and could also participate in the consolidation and extinction of aversive memories. Using hypocretin receptor-1 and hypocretin receptor-2 antagonists, hypocretin-1 and hypocretin-2 peptides, and hypocretin receptor-1 knockout mice, we investigated the role of the hypocretin system in cue- and context-dependent fear conditioning and extinction. Hypocretins were crucial for the consolidation of fear conditioning, and this effect was mainly observed in memories with a high emotional component. Notably, after the acquisition of fear memory, hypocretin receptor-1 blockade facilitated fear extinction, whereas hypocretin-1 administration impaired this extinction process. The extinction-facilitating effects of the hypocretin receptor-1 antagonist SB334867 were associated with increased expression of cFos in the basolateral amygdala and the infralimbic cortex. Intra-amygdala, but neither intra-infralimbic prefrontal cortex nor intra-dorsohippocampal infusion of SB334867 enhanced fear extinction. These results reveal a key role for hypocretins in the extinction of aversive memories and suggest that hypocretin receptor-1 blockade could represent a novel therapeutic target for the treatment of diseases associated with inappropriate retention of fear, such as post-traumatic stress disorder and phobias.

Indexed as

AmygdalaAnimalsBenzoxazolesExtinction, PsychologicalFearHippocampusIntracellular Signaling Peptides and ProteinsIsoquinolinesMaleMemoryMice, 129 StrainMice, Inbred C57BLMice, KnockoutNaphthyridinesNeuropeptidesOrexin Receptor Antagonists1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanoneBenzoxazolesHcrtr1 protein, mouseHcrtr2 protein, mouseIntracellular Signaling Peptides and ProteinsIsoquinolinesNaphthyridinesNeuropeptidesOrexin Receptor AntagonistsOrexin ReceptorsOrexinsProto-Oncogene Proteins c-fosPsychotropic DrugsPyridinesUrea

Identifiers

PMID24930888
PMCPMC4200503
OpenAlexW2069837577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.